High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Dana WestphalM GarzarolliM SergonPeter HorakBarbara HutterJ C BeckerM WiegelE MaczeySophia Freya Ulrike BlumS Grosche-SchleeA RüttenSelma UgurelAlbrecht StenzingerHanno GlimmDaniela E AustG BarettonStefan BeissertStefan FröhlingSilke RedlerHarald M SurowyFriedegund MeierPublished in: The British journal of dermatology (2021)
Molecular profiling demonstrated high TMB and EGFR/MAPK pathway activation to be novel therapeutic targets in mEPC.